Along the Central Dogma—Controlling Gene Expression with Small Molecules

Literature Cited

1. 1.  Theis N, Lerdau M 2003. The evolution of function in plant secondary metabolites. Int. J. Plant Sci. 164:S93–102
   [Google Scholar]
2. 2.  Newman DJ, Cragg GM 2012. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75:311–35
   [Google Scholar]
3. 3.  Li JWH, Vederas JC 2009. Drug discovery and natural products: end of an era or an endless frontier?. Science 325:161–65
   [Google Scholar]
4. 4.  Koehn FE, Carter GT 2005. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4:206–20
   [Google Scholar]
5. 5.  Harvey AL, Edrada-Ebel R, Quinn RJ 2015. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 14:111–29
   [Google Scholar]
6. 6.  Stent GS. 1968. That was the molecular biology that was. Science 160:390–95
   [Google Scholar]
7. 7.  Ahlquist P. 2002. RNA-dependent RNA polymerases, viruses, and RNA silencing. Science 296:1270–73
   [Google Scholar]
8. 8.  Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS 2005. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. 15:331–41
   [Google Scholar]
9. 9.  Chi P, Allis CD, Wang GG 2010. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10:457–69
   [Google Scholar]
10. 10.  Yoshida M, Kudo N, Kosono S, Ito A 2017. Chemical and structural biology of protein lysine deacetylases. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93:297–321
    [Google Scholar]
11. 11.  Lemon B, Tjian R 2000. Orchestrated response: a symphony of transcription factors for gene control. Genes Dev 14:2551–69
    [Google Scholar]
12. 12.  Darnell JE. 2002. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2:740–49
    [Google Scholar]
13. 13.  Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M 1997. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB. FEBS Lett 402:85–90
    [Google Scholar]
14. 14.  Gilmore TD. 2006. Introduction to NF-κB: players, pathways, perspectives. Oncogene 25:6680–84
    [Google Scholar]
15. 15.  Garcia-Pineres AJ, Castro V, Mora G, Schmidt TJ, Strunck E et al. 2001. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 276:39713–20
    [Google Scholar]
16. 16.  Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM 2001. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem. Biol. 8:759–66
    [Google Scholar]
17. 17.  Hehner SP, Hofmann TG, Droge W, Schmitz ML 1999. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. J. Immunol. 163:5617–23
    [Google Scholar]
18. 18.  Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA et al. 2007. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110:4427–35
    [Google Scholar]
19. 19.  Duan D, Zhang J, Yao J, Liu Y, Fang J 2016. Targeting thioredoxin reductase by parthenolide contributes to inducing apoptosis of HeLa cells. J. Biol. Chem. 291:10021–31
    [Google Scholar]
20. 20.  Ghantous A, Sinjab A, Herceg Z, Darwiche N 2013. Parthenolide: from plant shoots to cancer roots. Drug Discov. Today 18:894–905
    [Google Scholar]
21. 21.  Reich E, Franklin RM, Shatkin AJ, Tatum EL 1961. Effect of actinomycin D on cellular nucleic acid synthesis and virus production. Science 134:556–57
    [Google Scholar]
22. 22.  Goldberg IH, Rabinowitz M, Reich E 1962. Basis of actinomycin action. I. DNA binding and inhibition of RNA-polymerase synthetic reactions by actinomycin. PNAS 48:2094–101
    [Google Scholar]
23. 23.  Perry RP, Kelley DE 1970. Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J. Cell Physiol. 76:127–39
    [Google Scholar]
24. 24.  Wadkins RM, Vladu B, Tung CS 1998. Actinomycin D binds to metastable hairpins in single-stranded DNA. Biochemistry 37:11915–23
    [Google Scholar]
25. 25.  Rill RL, Hecker KH 1996. Sequence-specific actinomycin D binding to single-stranded DNA inhibits HIV reverse transcriptase and other polymerases. Biochemistry 35:3525–33
    [Google Scholar]
26. 26.  Kamitori S, Takusagawa F 1994. Multiple binding modes of anticancer drug actinomycin D: X-ray, molecular modeling, and spectroscopic studies of d(GAAGCTTC)2-actinomycin D complexes and its host DNA. J. Am. Chem. Soc. 116:4154–65
    [Google Scholar]
27. 27.  Hou MH, Robinson H, Gao YG, Wang AH 2002. Crystal structure of actinomycin D bound to the CTG triplet repeat sequences linked to neurological diseases. Nucleic Acids Res 30:4910–17
    [Google Scholar]
28. 28.  Maier JG, Harshaw WG 1967. Treatment and prognosis in Wilms’ tumor. A study of 51 cases with special reference to role of actinomycin D. Cancer 20:96–102
    [Google Scholar]
29. 29.  Schultz LD, Hall BD 1976. Transcription in yeast: α-amanitin sensitivity and other properties which distinguish between RNA polymerases I and III. PNAS 73:1029–33
    [Google Scholar]
30. 30.  Nguyen VT, Giannoni F, Dubois MF, Seo SJ, Vigneron M et al. 1996. In vivo degradation of RNA polymerase II largest subunit triggered by α-amanitin. Nucleic Acids Res 24:2924–29
    [Google Scholar]
31. 31.  Brueckner F, Cramer P 2008. Structural basis of transcription inhibition by α-amanitin and implications for RNA polymerase II translocation. Nat. Struct. Mol. Biol. 15:811–18
    [Google Scholar]
32. 32.  Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA et al. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275:28345–48
    [Google Scholar]
33. 33.  Chao SH, Price DH 2001. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276:31793–99
    [Google Scholar]
34. 34.  He QL, Titov DV, Li J, Tan M, Ye Z et al. 2015. Covalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolide. Angew. Chem. Int. Ed. Engl. 54:1859–63
    [Google Scholar]
35. 35.  Titov DV, Gilman B, He QL, Bhat S, Low WK et al. 2011. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat. Chem. Biol. 7:182–88
    [Google Scholar]
36. 36.  Jenuwein T, Allis CD 2001. Translating the histone code. Science 293:1074–80
    [Google Scholar]
37. 37.  Yang X, Lay F, Han H, Jones PA 2010. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 31:536–46
    [Google Scholar]
38. 38.  Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H et al. 2009. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–35
    [Google Scholar]
39. 39.  Ghoshal K, Datta J, Majumder S, Bai S, Kutay H et al. 2005. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 25:4727–41
    [Google Scholar]
40. 40.  Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG et al. 2009. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 69:4277–85
    [Google Scholar]
41. 41.  Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B 2010. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 38:4313–24
    [Google Scholar]
42. 42.  Erdmann A, Halby L, Fahy J, Arimondo PB 2015. Targeting DNA methylation with small molecules: What's next?. J. Med. Chem. 58:2569–83
    [Google Scholar]
43. 43.  Flotho C, Claus R, Batz C, Schneider M, Sandrock I et al. 2009. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23:1019–28
    [Google Scholar]
44. 44.  Rilova E, Erdmann A, Gros C, Masson V, Aussagues Y et al. 2014. Design, synthesis and biological evaluation of 4-amino-N-(4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. Chem. Med. Chem. 9:590–601
    [Google Scholar]
45. 45.  Allfrey VG, Faulkner R, Mirsky AE 1964. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. PNAS 51:786–94
    [Google Scholar]
46. 46.  Riggs MG, Whittaker RG, Neumann JR, Ingram VM 1977. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268:462–64
    [Google Scholar]
47. 47.  Yoshida M, Kijima M, Akita M, Beppu T 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265:17174–79
    [Google Scholar]
48. 48.  Richon VM, Webb Y, Merger R, Sheppard T, Jursic B et al. 1996. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. PNAS 93:5705–8
    [Google Scholar]
49. 49.  Taunton J, Hassig CA, Schreiber SL 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408–11
    [Google Scholar]
50. 50.  Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T 1993. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268:22429–35
    [Google Scholar]
51. 51.  Yoshida M, Horinouchi S, Beppu T 1995. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17:423–30
    [Google Scholar]
52. 52.  Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM et al. 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. PNAS 93:13143–47
    [Google Scholar]
53. 53.  Liesch JM, Sweeley CC, Staffeld GD, Anderson MS, Weber DJ, Scheffer RP 1982. Structure of HC-toxin, a cyclic tetrapeptide from Helminthosporium carbonum. Tetrahedron 38:45–48
    [Google Scholar]
54. 54.  Closse A, Huguenin R 1974. Isolation and structural clarification of chlamydocin. Helv. Chim. Acta 57:533–45
    [Google Scholar]
55. 55.  Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M et al. 2002. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916–21
    [Google Scholar]
56. 56.  Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N et al. 2001. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 61:4459–66
    [Google Scholar]
57. 57.  Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S 2001. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. PNAS 98:87–92
    [Google Scholar]
58. 58.  Hai Y, Christianson DW 2016. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nat. Chem. Biol. 12:741–47
    [Google Scholar]
59. 59.  Miyake Y, Keusch JJ, Wang L, Saito M, Hess D et al. 2016. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nat. Chem. Biol. 12:748–54
    [Google Scholar]
60. 60.  Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S et al. 2003. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758–66
    [Google Scholar]
61. 61.  Chen L, Fischle W, Verdin E, Greene WC 2001. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 293:1653–57
    [Google Scholar]
62. 62.  Bheda P, Jing H, Wolberger C, Lin H 2016. The substrate specificity of sirtuins. Annu. Rev. Biochem. 85:405–29
    [Google Scholar]
63. 63.  North BJ, Verdin E 2007. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLOS ONE 2:e784
    [Google Scholar]
64. 64.  Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF et al. 2005. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48:8045–54
    [Google Scholar]
65. 65.  Rumpf T, Schiedel M, Karaman B, Roessler C, North BJ et al. 2015. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat. Commun. 6:6263
    [Google Scholar]
66. 66.  Schuetz A, Min J, Antoshenko T, Wang CL, Allali-Hassani A et al. 2007. Structural basis of inhibition of the human NAD⁺-dependent deacetylase SIRT5 by suramin. Structure 15:377–89
    [Google Scholar]
67. 67.  Communi D, Robaye B, Boeynaems JM 1999. Pharmacological characterization of the human P2Y11 receptor. Br. J. Pharmacol. 128:1199–206
    [Google Scholar]
68. 68.  Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT et al. 2005. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18:601–7
    [Google Scholar]
69. 69.  Tan M, Luo H, Lee S, Jin F, Yang JS et al. 2011. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146:1016–28
    [Google Scholar]
70. 70.  Chen Y, Sprung R, Tang Y, Ball H, Sangras B et al. 2007. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell Proteom. 6:812–19
    [Google Scholar]
71. 71.  Smith BC, Denu JM 2007. Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. J. Biol. Chem. 282:37256–65
    [Google Scholar]
72. 72.  Peng C, Lu Z, Xie Z, Cheng Z, Chen Y et al. 2011. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol. Cell Proteom. 10:M111.012658
    [Google Scholar]
73. 73.  Du J, Zhou Y, Su X, Yu JJ, Khan S et al. 2011. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334:806–9
    [Google Scholar]
74. 74.  Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A et al. 2004. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 279:33716–26
    [Google Scholar]
75. 75.  Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB et al. 2004. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279:51163–71
    [Google Scholar]
76. 76.  Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K et al. 2012. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4:145ra04
    [Google Scholar]
77. 77.  Fukuda I, Ito A, Hirai G, Nishimura S, Kawasaki H et al. 2009. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 16:133–40
    [Google Scholar]
78. 78.  Bowers EM, Yan G, Mukherjee C, Orry A, Wang L et al. 2010. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17:471–82
    [Google Scholar]
79. 79.  Yan G, Eller MS, Elm C, Larocca CA, Ryu B et al. 2013. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J. Invest. Dermatol. 133:2444–52
    [Google Scholar]
80. 80.  Oike T, Komachi M, Ogiwara H, Amornwichet N, Saitoh Y et al. 2014. C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe. Radiother. Oncol. 111:222–27
    [Google Scholar]
81. 81.  Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S et al. 2010. Suppression of inflammation by a synthetic histone mimic. Nature 468:1119–23
    [Google Scholar]
82. 82.  Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB et al. 2010. Selective inhibition of BET bromodomains. Nature 468:1067–73
    [Google Scholar]
83. 83.  Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z et al. 2014. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. PNAS 111:E2721–30
    [Google Scholar]
84. 84.  Ito T, Umehara T, Sasaki K, Nakamura Y, Nishino N et al. 2011. Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem. Biol. 18:495–507
    [Google Scholar]
85. 85.  Nakaoka S, Sasaki K, Ito A, Nakao Y, Yoshida M 2016. A genetically encoded FRET probe to detect intranucleosomal histone H3K9 or H3K14 acetylation using BRD4, a BET family member. ACS Chem. Biol. 11:729–33
    [Google Scholar]
86. 86.  Tachibana M, Sugimoto K, Fukushima T, Shinkai Y 2001. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J. Biol. Chem. 276:25309–17
    [Google Scholar]
87. 87.  Casciello F, Windloch K, Gannon F, Lee JS 2015. Functional role of G9a histone methyltransferase in cancer. Front. Immunol. 6:487
    [Google Scholar]
88. 88.  Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A 2005. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1:143–45
    [Google Scholar]
89. 89.  Cherblanc FL, Chapman KL, Brown R, Fuchter MJ 2013. Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat. Chem. Biol. 9:136–37
    [Google Scholar]
90. 90.  Cherblanc FL, Chapman KL, Reid J, Borg AJ, Sundriyal S et al. 2013. On the histone lysine methyltransferase activity of fungal metabolite chaetocin. J. Med. Chem. 56:8616–25
    [Google Scholar]
91. 91.  Fujishiro S, Dodo K, Iwasa E, Teng Y, Sohtome Y et al. 2013. Epidithiodiketopiperazine as a pharmacophore for protein lysine methyltransferase G9a inhibitors: reducing cytotoxicity by structural simplification. Bioorg. Med. Chem. Lett. 23:733–36
    [Google Scholar]
92. 92.  Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q et al. 2007. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25:473–81
    [Google Scholar]
93. 93.  Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ et al. 2010. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J. Med. Chem. 53:5844–57
    [Google Scholar]
94. 94.  Kim KH, Roberts CW 2016. Targeting EZH2 in cancer. Nat. Med. 22:128–34
    [Google Scholar]
95. 95.  McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C et al. 2012. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108–12
    [Google Scholar]
96. 96.  Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ et al. 2013. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. PNAS 110:7922–27
    [Google Scholar]
97. 97.  Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L et al. 2013. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122:1017–25
    [Google Scholar]
98. 98.  Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG et al. 2015. A phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in adults with relapsed or refractory leukemia: safety, clinical activity, exposure and target inhibition. Blood 126:2547
    [Google Scholar]
99. 99.  Casper A, Van Doren M 2006. The control of sexual identity in the Drosophila germline. Development 133:2783–91
    [Google Scholar]
100. 100.  Harper SJ, Bates DO 2008. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat. Rev. Cancer 8:880–87
     [Google Scholar]
101. 101.  Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M et al. 2007. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3:576–83
     [Google Scholar]
102. 102.  Corrionero A, Minana B, Valcarcel J 2011. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 25:445–59
     [Google Scholar]
103. 103.  Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H et al. 2007. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3:570–75
     [Google Scholar]
104. 104.  Furumai R, Uchida K, Komi Y, Yoneyama M, Ishigami K et al. 2010. Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF. Cancer Sci 101:2483–89
     [Google Scholar]
105. 105.  Khan K, Schneider-Poetsch T, Ishfaq M, Ito A, Yoshimoto R et al. 2014. Splicing inhibition induces gene expression through canonical NF-κB pathway and extracellular signal-related kinase activation. FEBS Lett 588:1053–57
     [Google Scholar]
106. 106.  Koga M, Satoh T, Takasaki I, Kawamura Y, Yoshida M, Kaida D 2014. U2 snRNP is required for expression of the 3′ end of genes. PLOS ONE 9:e98015
     [Google Scholar]
107. 107.  Kim S, Kim H, Fong N, Erickson B, Bentley DL 2011. Pre-mRNA splicing is a determinant of histone H3K36 methylation. PNAS 108:13564–69
     [Google Scholar]
108. 108.  Folco EG, Coil KE, Reed R 2011. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev 25:440–44
     [Google Scholar]
109. 109.  O'Brien K, Matlin AJ, Lowell AM, Moore MJ 2008. The biflavonoid isoginkgetin is a general inhibitor of pre-mRNA splicing. J. Biol. Chem. 283:33147–54
     [Google Scholar]
110. 110.  Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano H et al. 2011. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat. Commun. 2:308
     [Google Scholar]
111. 111.  Sakuma M, Iida K, Hagiwara M 2015. Deciphering targeting rules of splicing modulator compounds: case of TG003. BMC Mol. Biol. 16:16
     [Google Scholar]
112. 112.  Palacino J, Swalley SE, Song C, Cheung AK, Shu L et al. 2015. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat. Chem. Biol. 11:511–17
     [Google Scholar]
113. 113.  Hua Y, Sahashi K, Hung G, Rigo F, Passini MA et al. 2010. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24:1634–44
     [Google Scholar]
114. 114.  Wan L, Dreyfuss G 2017. Splicing-correcting therapy for SMA. Cell 170:5
     [Google Scholar]
115. 115.  Nguyen KT, Holloway MP, Altura RA 2012. The CRM1 nuclear export protein in normal development and disease. Int. J. Biochem. Mol. Biol. 3:137–51
     [Google Scholar]
116. 116.  Kudo N, Khochbin S, Nishi K, Kitano K, Yanagida M et al. 1997. Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J. Biol. Chem. 272:29742–51
     [Google Scholar]
117. 117.  Fornerod M, Ohno M, Yoshida M, Mattaj IW 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:1051–60
     [Google Scholar]
118. 118.  Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M et al. 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390:308–11
     [Google Scholar]
119. 119.  Culjkovic-Kraljacic B, Borden KL 2013. Aiding and abetting cancer: mRNA export and the nuclear pore. Trends Cell Biol 23:328–35
     [Google Scholar]
120. 120.  Gallouzi IE, Steitz JA 2001. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science 294:1895–901
     [Google Scholar]
121. 121.  Culjkovic B, Borden KL 2009. Understanding and targeting the eukaryotic translation initiation factor eIF4E in head and neck cancer. J. Oncol. 2009:981679
     [Google Scholar]
122. 122.  Dickmanns A, Monecke T, Ficner R 2015. Structural basis of targeting the exportin CRM1 in cancer. Cells 4:538–68
     [Google Scholar]
123. 123.  Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H et al. 2013. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. PNAS 110:1303–8
     [Google Scholar]
124. 124.  Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y et al. 1998. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 242:540–47
     [Google Scholar]
125. 125.  Newlands ES, Rustin GJ, Brampton MH 1996. Phase I trial of elactocin. Br. J. Cancer 74:648–49
     [Google Scholar]
126. 126.  Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A et al. 2016. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. Leukemia 30:190–99
     [Google Scholar]
127. 127.  Kalid O, Toledo Warshaviak D, Shechter S, Sherman W, Shacham S 2012. Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J. Comput. Aided Mol. Des. 26:1217–28
     [Google Scholar]
128. 128.  Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G et al. 2016. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature 538:114–17
     [Google Scholar]
129. 129.  Singh G, Kucukural A, Cenik C, Leszyk JD, Shaffer SA et al. 2012. The cellular EJC interactome reveals higher-order mRNP structure and an EJC-SR protein nexus. Cell 151:750–64
     [Google Scholar]
130. 130.  Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R et al. 2006. Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev 20:355–67
     [Google Scholar]
131. 131.  Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS et al. 2007. Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J. Cell Biol. 178:1145–60
     [Google Scholar]
132. 132.  Ishigaki Y, Li X, Serin G, Maquat LE 2001. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell 106:607–17
     [Google Scholar]
133. 133.  Miyamoto Y, Machida K, Mizunuma M, Emoto Y, Sato N et al. 2002. Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G₁-specific inhibitor reveromycin A. J. Biol. Chem. 277:28810–14
     [Google Scholar]
134. 134.  Osada H. 2016. Chemical and biological studies of reveromycin A. J. Antibiot. 69:723–30
     [Google Scholar]
135. 135.  Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M et al. 2012. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat. Chem. Biol. 8:311–17
     [Google Scholar]
136. 136.  Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T et al. 2007. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316:1759–61
     [Google Scholar]
137. 137.  Fonseca BD, Smith EM, Yelle N, Alain T, Bushell M, Pause A 2014. The ever-evolving role of mTOR in translation. Semin. Cell Dev. Biol. 36:102–12
     [Google Scholar]
138. 138.  Low WK, Dang Y, Schneider-Poetsch T, Shi Z, Choi NS et al. 2005. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol. Cell 20:709–22
     [Google Scholar]
139. 139.  Dang Y, Low WK, Xu J, Gehring NH, Dietz HC et al. 2009. Inhibition of nonsense-mediated mRNA decay by the natural product pateamine A through eukaryotic initiation factor 4AIII. J. Biol. Chem. 284:23613–21
     [Google Scholar]
140. 140.  Dang Y, Kedersha N, Low WK, Romo D, Gorospe M et al. 2006. Eukaryotic initiation factor 2α-independent pathway of stress granule induction by the natural product pateamine A. J. Biol. Chem. 281:32870–78
     [Google Scholar]
141. 141.  Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS et al. 2006. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2:213–20
     [Google Scholar]
142. 142.  Tillotson J, Kedzior M, Guimarães L, Ross AB, Peters TL et al. 2017. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A. Bioorg. Med. Chem. Lett. 27:4082–85
     [Google Scholar]
143. 143.  Iwasaki S, Floor SN, Ingolia NT 2016. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor. Nature 534:558–61
     [Google Scholar]
144. 144.  Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R et al. 2009. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLOS ONE 4:e5223
     [Google Scholar]
145. 145.  Lindqvist L, Robert F, Merrick W, Kakeya H, Fraser C et al. 2010. Inhibition of translation by cytotrienin A–a member of the ansamycin family. RNA 16:2404–13
     [Google Scholar]
146. 146.  Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM 2001. Homoharringtonine: history, current research, and future direction. Cancer 92:1591–605
     [Google Scholar]
147. 147.  Gurel G, Blaha G, Moore PB, Steitz TA 2009. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J. Mol. Biol. 389:146–56
     [Google Scholar]
148. 148.  McClary B, Zinshteyn B, Meyer M, Jouanneau M, Pellegrino S et al. 2017. Inhibition of eukaryotic translation by the antitumor natural product agelastatin A. Cell Chem. Biol. 24:605–13.e5
     [Google Scholar]
149. 149.  de Loubresse NG, Prokhorova I, Holtkamp W, Rodnina MV, Yusupova G, Yusupov M 2014. Structural basis for the inhibition of the eukaryotic ribosome. Nature 513:517–22
     [Google Scholar]
150. 150.  Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I 2015. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14:261–78
     [Google Scholar]
151. 151.  Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S et al. 2010. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat. Chem. Biol. 6:209–17
     [Google Scholar]
152. 152.  Dang Y, Schneider-Poetsch T, Eyler DE, Jewett JC, Bhat S et al. 2011. Inhibition of eukaryotic translation elongation by the antitumor natural product Mycalamide B. RNA 17:1578–88
     [Google Scholar]
153. 153.  Lee S, Liu B, Huang SX, Shen B, Qian SB 2012. Global mapping of translation initiation sites in mammalian cells at single-nucleotide resolution. PNAS 109:E2424–32
     [Google Scholar]
154. 154.  Han Y, Gao X, Liu B, Wan J, Zhang X, Qian SB 2014. Ribosome profiling reveals sequence-independent post-initiation pausing as a signature of translation. Cell Res 24:842–51
     [Google Scholar]